Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1314885 | 1.00 | RAB9A (0.53) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5749113 | 1.00 | RAB9A (0.53) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3925184 | 0.98 | KDM4E (0.50) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14234938 | 0.92 | KDM4E (0.44) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8199541 | 0.84 | KDM4E (0.39) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL30542615 | 0.79 | RAB9A (0.55) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29058183 | 0.79 | RAB9A (0.55) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28879024 | 0.79 | RAB9A (0.55) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL18626629 | 0.79 | KCNH2 (0.50) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22368184 | 0.79 | RAB9A (0.55) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738606-B2 | Substituted diarylamines and use of same as antioxidants | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2017-08-22 | — | — | US | disclosed |
| US-20140206585-A1 | Substituted Diarylamines and Use of Same as Antioxidants | UNIVERSITA DI BOLOGNA (IT) | 2014-07-24 | — | — | US | disclosed |
| WO-2012162818-A1 | SUBSTITUTED DIARYLAMINES AND USE OF SAME AS ANTIOXIDANTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2012-12-06 | — | — | WO | disclosed |
| US-20060293503-A1 | Polyaminopyridines and method for producing same | SUMITOMO SEIKA CHEMICALS CO., LTD (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1669390-A1 | POLYAMINOPYRIDINES AND METHOD FOR PRODUCING SAME | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206585-A1 | Substituted Diarylamines and Use of Same as Antioxidants | SOD1, NQO1, GPX1 | RAB9A 994/4885KDM4E 1391/4885ALDH1A1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.